These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

968 related items for PubMed ID: 18927288

  • 1. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
    Clin Cancer Res; 2008 Oct 15; 14(20):6487-95. PubMed ID: 18927288
    [Abstract] [Full Text] [Related]

  • 2. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells.
    Tomita Y, Imai K, Senju S, Irie A, Inoue M, Hayashida Y, Shiraishi K, Mori T, Daigo Y, Tsunoda T, Ito T, Nomori H, Nakamura Y, Kohrogi H, Nishimura Y.
    Cancer Sci; 2011 Apr 15; 102(4):697-705. PubMed ID: 21231984
    [Abstract] [Full Text] [Related]

  • 3. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, Ishihara Y, Itoh K.
    Clin Cancer Res; 2004 Sep 01; 10(17):5828-36. PubMed ID: 15355913
    [Abstract] [Full Text] [Related]

  • 4. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y.
    Clin Cancer Res; 2006 May 01; 12(9):2689-97. PubMed ID: 16675560
    [Abstract] [Full Text] [Related]

  • 5. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K, Sasada T, Takedatsu H, Shomura H, Koga M, Maeda Y, Yao A, Hirai T, Takabayashi A, Shichijo S, Itoh K.
    Clin Cancer Res; 2004 Oct 01; 10(19):6695-702. PubMed ID: 15475460
    [Abstract] [Full Text] [Related]

  • 6. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ.
    Eur J Immunol; 1997 May 01; 27(5):1115-23. PubMed ID: 9174600
    [Abstract] [Full Text] [Related]

  • 7. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T, Tanaka F, Mori M, Takesako K, Sugimachi K, Akiyoshi T.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [Abstract] [Full Text] [Related]

  • 8. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H, Hirohashi Y, Torigoe T, Asanuma H, Hariu M, Tamura Y, Aketa K, Nabeta C, Nakanishi K, Kamiguchi K, Mano Y, Kitamura H, Kobayashi J, Tsukahara T, Shijubo N, Sato N.
    Clin Cancer Res; 2005 Feb 01; 11(3):1000-9. PubMed ID: 15709165
    [Abstract] [Full Text] [Related]

  • 9. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.
    Cancer Res; 2005 Jul 15; 65(14):6435-42. PubMed ID: 16024648
    [Abstract] [Full Text] [Related]

  • 10. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
    Jaramillo A, Narayanan K, Campbell LG, Benshoff ND, Lybarger L, Hansen TH, Fleming TP, Dietz JR, Mohanakumar T.
    Breast Cancer Res Treat; 2004 Nov 15; 88(1):29-41. PubMed ID: 15538043
    [Abstract] [Full Text] [Related]

  • 11. Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer.
    Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tomita Y, Tsunoda T, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
    Br J Cancer; 2011 Jan 18; 104(2):300-7. PubMed ID: 21179034
    [Abstract] [Full Text] [Related]

  • 12. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K, Itoh T, Kawashima I, Takesako K, Mazda O, Nukaya I, Yano Y, Yamamoto Y, Yamagishi H, Ueda Y.
    Oncol Rep; 2004 Oct 18; 12(4):725-31. PubMed ID: 15375491
    [Abstract] [Full Text] [Related]

  • 13. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y.
    Clin Cancer Res; 2004 Dec 15; 10(24):8630-40. PubMed ID: 15623647
    [Abstract] [Full Text] [Related]

  • 14. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
    Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.
    Cancer; 2009 Feb 15; 115(4):800-11. PubMed ID: 19117353
    [Abstract] [Full Text] [Related]

  • 15. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.
    Nikitina EY, Clark JI, Van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI.
    Clin Cancer Res; 2001 Jan 15; 7(1):127-35. PubMed ID: 11205900
    [Abstract] [Full Text] [Related]

  • 16. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
    Peiper M, Goedegebuure PS, Izbicki JR, Eberlein TJ.
    Anticancer Res; 1999 Jan 15; 19(4A):2471-5. PubMed ID: 10470176
    [Abstract] [Full Text] [Related]

  • 17. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ.
    J Immunol; 1995 Nov 01; 155(9):4486-91. PubMed ID: 7594611
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
    Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H.
    Clin Cancer Res; 2006 Oct 01; 12(19):5841-9. PubMed ID: 17020992
    [Abstract] [Full Text] [Related]

  • 19. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers.
    Inoue M, Senju S, Hirata S, Ikuta Y, Hayashida Y, Irie A, Harao M, Imai K, Tomita Y, Tsunoda T, Furukawa Y, Ito T, Nakamura Y, Baba H, Nishimura Y.
    Int J Cancer; 2010 Sep 01; 127(6):1393-403. PubMed ID: 20063317
    [Abstract] [Full Text] [Related]

  • 20. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
    Tanaka Y, Amos KD, Fleming TP, Eberlein TJ, Goedegebuure PS.
    Surgery; 2003 Jan 01; 133(1):74-80. PubMed ID: 12563241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.